GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing

Informacje na temat projektu

GATBIO NEXT

Identyfikator umowy o grant: 101114204

DOI

10.3030/101114204

Projekt został zamknięty

Data podpisania przez KE 31 Maja 2023

Data rozpoczęcia 1 Czerwca 2023

Data zakończenia 31 Maja 2024

Finansowanie w ramach

• European innovation ecosystems

Koszt całkowity

Brak danych

Wkład UE

€ 75 000,00

Koordynowany przez

GAT BIOSCIENCES SL
Spain

Periodic Reporting for period 1 - GATBIO NEXT (GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing)

Okres sprawozdawczy: 2023-06-01 do 2024-05-31

Podsumowanie kontekstu i ogólnych celów projektu

GAT Biosciences S.L. (GATBIO) is a preclinical stage Biotech SME developing next generation of accessible and non-injected (oral) biopharmaceuticals through proprietary and sustainable microalgal biofactories. Our first candidate is GB-AF-004, an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases (IBDs). GB-AF-004 has the potential to highly impact the quality of life of millions of IBD’s patients worldwide as an affordable, low toxicity and long-term efficacy therapy for Ulcerative Colitis and Crohn's patients.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

GATBIO’s WomenTechEu Project has explored the best therapeutic positioning for GB-AF-004, based on a deep analysis of current therapeutic options for IBD and their limitations, working in collaboration with leaders of opinion in the clinical management of IBD.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Biologic anti-inflammatory therapies have already proven to be highly effective treatments for the induction and remission control of IBD's flares. Still, all available anti-inflammatory biologics are administered by injection and their systemic administration is related to site-effects and middle-terms loss of efficacy. GB-AF-004, a new class of anti-inflammatory antibody of enhanced properties to harsh intestinal atmosphere, has the potential to become the first oral anti-inflammatory biologic for IBDs management, acting specifically and locally in the damaged intestinal tissue without systemic immunosuppression and for long-term non-invasive, accessible and affordable treatments. IBDs includes a range of chronic and painful autoimmune diseases affecting locally the intestine, affecting patients from their youth and throughout life and of unknown causes. More than 10 million people are affected by IBD.